Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed\* hepatocellular carcinoma
• •* Unresectable disease
• •* Child's class A or B with liver-predominant and asymptomatic extrahepatic disease NOTE: \*A highly suspicious liver mass on CT scan or MRI in the presence of alpha fetoprotein \> 200 mg/dL may be used as alternative diagnostic criterion
• •PATIENT CHARACTERISTICS:
• •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• •Absolute neutrophil count \> 1,500/mm³
• •Platelet count \> 50,000/mm³
• •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5.0 times upper limit of normal (ULN)
• •Bilirubin ≤ 5.0 mg/dL
• •Creatinine normal OR creatinine clearance \> 50 mL/min
• •No significant traumatic injury within the past 28 days
• •No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
• •No serious, nonhealing wound, ulcer, or bone fracture
• •PRIOR CONCURRENT THERAPY:
• •No major surgery or open biopsy within the past 28 days
• •No minor surgery (e.g., fine-needle aspirations or core biopsies) within the past 7 days
• •No chemotherapy within the past 4 weeks
• •No radiotherapy within the past 21 days
• •No concurrent major surgery
• •No other concurrent chemotherapy
• •No other concurrent investigational drugs